April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
COVID-19 Pandemic Delays Treatment for HCC, Says French Cancer Center Analysis
October 8th 2020In patients with advanced hepatocellular carcinoma treated in 2020, there was an observed decrease in planned treatment as well as significant delays noted as a result of the coronavirus disease 2019 pandemic, according to the results of a study of 6 academic referral centers.
Read More
Expert Recognizes Expansion of HCC Treatment Options During Liver Cancer Awareness Month
October 7th 2020In an interview with Targeted Oncology, David J. Pinato, MD, PhD, reviewed how the treatment landscape of hepatocellular carcinoma has evolved over the years and the challenges that clinicians and researchers currently face in the field.
Read More
Neoadjuvant Nivolumab Plus Electroporation With Curative Intent Safe and Possible in HCC
October 6th 2020Neoadjuvant immunotherapy with nivolumab plus percutaneous electroporation has demonstrated early signals of promise in the treatment of patients with Barcelona Clinic Liver Cancer class A hepatocellular carcinoma, according to preliminary reports from the phase 2 NIVOLEP trial.
Read More
In Light of Recently Approved Regimens, Sequencing Strategies Are Under Discussion in HCC
October 5th 2020Laura Goff, MD, discussed the combination of atezolizumab plus bevacizumab in relation to its effect on the treatment paradigm of hepatocellular carcinoma during a presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.
Read More
ILCA Data Reignite Interest in AFP as a Biomarker for HCC
October 4th 2020Although the use of α-fetoprotein has long been established in hepatocellular carcinoma as a biomarker for screening and diagnosis, its role in treatment selection and prognosis following systemic therapy is a moving target.
Read More
HCC Treatment Paradigm Evolves Rapidly, Abou-Alfa Says During Liver Cancer Awareness Month
October 1st 2020In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discussed the evolution of the liver cancer treatment landscape and recognizes some of most important advances in the field during Liver Cancer Awareness Month.
Read More
Camrelizumab Plus Apatinib Achieves High Response Rates in Advanced Hepatocellular Carcinoma
September 29th 2020Camrelizumab plus apatinib demonstrated a high objective response rate and disease-control rate, as well as durable responses and long survival as treatment of patients with advanced hepatocellular carcinoma, according to the results from the phase 2 RESCUE clinical trial.
Read More
IV Sintilimab and Bevacizumab Biosimilar Improve Survival in Frontline Advanced HCC
September 28th 2020The sintilimab injection in combination with IBI305, a biosimilar to bevacizumab, improved overall survival as well as progression-free survival compared with sorafenib as front-line treatment of patients with advanced hepatocellular carcinoma, meeting the predefined primary end point of the phase 3 ORIENT-32 clinical trial.
Read More
Survival Improved With HAIC Over Standard TACE in Unresectable HCC
September 20th 2020A significant improvement in overall survival was observed with the addition of hepatic arterial infusion chemotherapy to oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Read More
Real-World Study Confirms Safety of Regorafenib After Sorafenib in Unresectable HCC
September 14th 2020Regorafenib demonstrated a tolerable safety profile as treatment of patients with unresectable hepatocellular carcinoma in the real world, according to results from the ongoing prospective observational REFINE study.
Read More